Abstract
Pain in patients with impaired renal function may be a significant problem requiring treatment with opioids. However, pharmacokinetic and metabolic changes associated with an impaired renal function may raise some concerns about side effects and overdosing associated with opioid agents in this patients population. In order to give recommendations on this issue, we review the available evidences on the pharmacokinetics and side effects of most common opioids used to treat pain. The results of this review show that the half-life of the parent opioid compounds and of their metabolites is increased in the presence of renal dysfunction, for which careful monitoring of the patient, dose reduction and a longer time interval between doses are recommended. Among opioids, morphine and codeine used with great caution and possibly avoided in renal failure/dialysis patients; tramadol, hydromorphone and oxycodone can be used with caution and close patients monitoring, whereas transdermal buprenorphine, methadone and fentanyl/sufentanil appear to be safe to use in patients with renal failure.
Keywords: Analgesia, analgesics, buprenorphine, dialysis kidney, morphine, opioids, oxycodone, pain, renal failure
Current Drug Targets
Title: The Use of Major Analgesics in Patients with Renal Dysfunction
Volume: 11 Issue: 6
Author(s): Pasquale Niscola, Laura Scaramucci, Gisella Vischini, Marco Giovannini, Michele Ferrannini, Pasquale Massa, Paola Tatangelo, Massimo Galletti and Roberto Palumbo
Affiliation:
Keywords: Analgesia, analgesics, buprenorphine, dialysis kidney, morphine, opioids, oxycodone, pain, renal failure
Abstract: Pain in patients with impaired renal function may be a significant problem requiring treatment with opioids. However, pharmacokinetic and metabolic changes associated with an impaired renal function may raise some concerns about side effects and overdosing associated with opioid agents in this patients population. In order to give recommendations on this issue, we review the available evidences on the pharmacokinetics and side effects of most common opioids used to treat pain. The results of this review show that the half-life of the parent opioid compounds and of their metabolites is increased in the presence of renal dysfunction, for which careful monitoring of the patient, dose reduction and a longer time interval between doses are recommended. Among opioids, morphine and codeine used with great caution and possibly avoided in renal failure/dialysis patients; tramadol, hydromorphone and oxycodone can be used with caution and close patients monitoring, whereas transdermal buprenorphine, methadone and fentanyl/sufentanil appear to be safe to use in patients with renal failure.
Export Options
About this article
Cite this article as:
Niscola Pasquale, Scaramucci Laura, Vischini Gisella, Giovannini Marco, Ferrannini Michele, Massa Pasquale, Tatangelo Paola, Galletti Massimo and Palumbo Roberto, The Use of Major Analgesics in Patients with Renal Dysfunction, Current Drug Targets 2010; 11 (6) . https://dx.doi.org/10.2174/138945010791170879
DOI https://dx.doi.org/10.2174/138945010791170879 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Invasive Aspergillosis: New Insights into Disease, Diagnostic and Treatment
Current Pharmaceutical Design The Use of Biomarkers for Assessing HAART-Associated Renal Toxicity in HIV-Infected Patients
Current HIV Research Phytochemical and Pharmacological Insight on Sesamol: An Updated Review
Current Bioactive Compounds A Review of the Chemical and Pharmacological Aspects of the Genus Marrubium
Current Pharmaceutical Design Role of CGRP-Receptor Component Protein (RCP) in CLR/RAMP Function
Current Protein & Peptide Science Amiodarone - A ‘Broad Spectrum’ Antiarrhythmic Drug
Cardiovascular & Hematological Disorders-Drug Targets Endocannabinoid Blockade and the Cardiovascular System
Current Drug Therapy Pyrazoline: A Promising Scaffold for the Inhibition of Monoamine Oxidase
Central Nervous System Agents in Medicinal Chemistry Role of Salt and Potassium in Hypertension and the Associated Organ Damages
Current Hypertension Reviews Dissections of the Thoracic Aorta and Evolving Endovascular Strategies
Current Hypertension Reviews Platelets and Atherothrombosis: Causes, Targets and Treatments for Thrombosis
Current Medicinal Chemistry Therapeutic Hypothermia and Neuroprotection in Acute Neurological Disease
Current Medicinal Chemistry Medical Treatment of Uterine Arteriovenous Malformations: A Case Report
Current Women`s Health Reviews Anti-Atherosclerotic Therapy Based on Botanicals
Recent Patents on Cardiovascular Drug Discovery Safety of Nanoparticles in Medicine
Current Drug Targets Polypharmacy in Cardiovascular Medicine: Problems and Promises!
Cardiovascular & Hematological Agents in Medicinal Chemistry Alpha-2 Adrenoceptor Ligands and Opioid Drugs: Pharmacological Interactions of Therapeutic Interest
Current Neuropharmacology Applications and Modifications of 1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic Acid (Tic) in Peptides and Peptidomimetics Design and Discovery
Current Protein & Peptide Science Method Validation and Simultaneous Determination of Retinol, Retinyl Palmitate, β-Carotene, α-Tocopherol and Vitamin C in Rat Serum Treated with 7,12 Dimethylbenz[a]Anthracene and Plantago major L. by High- Performance Liquid Chromatography Using Diode-Array Detection
Combinatorial Chemistry & High Throughput Screening Current Understanding of Polymyxin B Applications in Bacteraemia/ Sepsis Therapy Prevention: Clinical, Pharmaceutical, Structural and Mechanistic Aspects
Anti-Infective Agents in Medicinal Chemistry